• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Investigation Report on China Imatinib Market, 2009-2018 Product Image

Investigation Report on China Imatinib Market, 2009-2018

  • Published: March 2014
  • Region: China
  • 40 Pages
  • China Research & Intelligence

FEATURED COMPANIES

  • Hansoh Pharmaceutical
  • Novartis
  • MORE

Incidence of chronic myelogenous leukemia (CML) varies in the world. The global incidence is about 10/1,000,000 while in China it is 4/1,000,000. CML takes up about 20% of leukaemia in China and 95% of chronic leukemia. CML patients vary from the very young to the very old, and the incidence increases as people grow old.

CML treatment went through a long period of development. Interferon used to be main medication before imatinib. It was initially used in CML treatment in 1980 and became the first genetically effective drug to treat chronic phase CML-CP since 1990. About 20% to 30% patients get cytogenetic remission and live longer using interferon. However, interferon is toxic because of too many unbearable side effects.

Imatinib is originally developed by Novartis with the trade name ""Gleevec"". It was approved to the U.S.A. to treat Philadelphia chromosome-positive chronic myeloid leukemia (CML) blastic phase, accelerated phase or patients in chronic phase after a-interferon failure. In November 2001 it was approved in Europe and to Chinese market in April 2002. Average survival time of CML patients used to be 3 to 6 years before imatinib was developed. Due to its READ MORE >

1 Relevant Concepts of Imatinib
1.1 Indication
1.2 Sales Status on the Global Market

2 Market Overview of Imatinib in China, 2010-2013
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size

3 Investigation on Sales Value of Imatinib in China, 2010-2013
3.1 Total Sales Value
3.2 Sales Value by Region

4 Investigation on Market Share of Major Imatinib Manufacturers in China, 2010-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Investigation on Market Size of Imatinib by Dosage Form in China, 2010-2013
5.1 Market Share by Sales Value and Dosage Form
5.2 Market Share by Sales Volume and Dosage Form

6 Reference Price of Imatinib Produced by Different Enterprises in China Hospital Market, 2014
6.1 Novartis
6.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
6.3 Hansoh Pharmaceutical

7 Major Manufacturing Enterprises in China Imatinib Market, 2009-2014
7.1 Novartis
7.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
7.3 Hansoh Pharmaceutical

8 Prospect of China Imatinib Market, 2014-2018
8.1 Forecast on Incidence of CML
8.2 Manufacturing Schedule of Generic Drug
8.3 Forecast on Market Size
8.4 Forecast on Competition Pattern

Selected Charts

Chart Imatinib Products Approved to Market in China, 2014
Chart Forecast on Market Size of Hospital-use Imatinib in China, 2014-2018
Chart Sales Value of Imatinib in Global Market, 2010-2013
Chart Sales Value of Imatinib in China Hospital Market, 2010-2013
Chart Sales Value of Imatinib by Region in China, 2010-2013
Chart Market Share of Imatinib Enterprises by Sales Value in China, 2010-2013
Chart Price of Imatinib Produced by Novartis in China Hospital Market, 2014
Chart Price of Imatinib Produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. in China Hospital Market, 2014

- Novartis
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Hansoh Pharmaceutical

Note: Product cover images may vary from those shown

ALSO AVAILABLE IN THE FOLLOWING LANGUAGES

RELATED PRODUCTS

Our Clients

Our clients' logos